Search

Objective: The aim of this study is to evaluate the effects of dietary changes on late phase of allergic reaction in patients with allergic rhinitis (AR) by measuring eosinophilic cationic protein (ECP), interleukin (IL)-4 and IL-31 levels. Methods: Sixty participants (40 patients with AR and 20 healthy control subjects) were included in this study. Forty patients with confirmed diagnosis of AR were randomly divided into two groups, all patients were prescribed the same treatment, intranasal azelastine hydrochloride. Patients in group 1 were asked to change their diet from Western to Mediterranean diet by eliminating processed meat, processed sugar, and polyunsaturated fatty acids. Blood samples of every subject were driven at the beginning and three months later to study ECP, IL-4 and IL- 31 levels. By using ELISA method IL-4 and IL-31 levels were determined and compared between healthy volunteers and patients. Results: There was a significant difference in terms of ECP levels in group 2. The posttreatment ECP levels were significantly higher than pretreatment levels in group 2 (p=0.025 and p<0.05). There was no significant difference in terms of other parameters. Conclusion: In our study, we showed that the laboratory parameters associated with AR were positively affected by the Mediterranean diet. [ABSTRACT FROM AUTHOR]

Objectives: This study aimed to evaluate how Rhinapi nasal spray affects symptoms of allergic rhinitis. Methods: In this prospective, multicenter, observational study, 10,000 patients (comprising 5028 males and 4972 females) exhibiting symptoms of allergic rhinitis (namely, nasal discharge, sneezing, nasal itching, and nasal obstruction) from different centers in different regions of Turkey were enrolled in the study between March 2022 and March 2023. All the patients wanted to participate in the study and were administered Rhinapi one puff to each nostril three times a day, for a period of 3 weeks. Total symptom scores, quality of life (QoL) scores, and otolaryngological examination scores were evaluated before and 3 weeks after treatment. Results: The scores for discharge from the nose, sneezing, nasal pruritus, and blockage of the nose all indicated improvement when compared to pre-medication and post-medication. This difference achieved statistical significance (P <.001). The mean total symptom score fell following treatment (P <.001): whilst the score was 11.09 ± 3.41 before administering Rhinapi; after administration, the average score was 6.23 ± 2.41. The mean QoL scores also altered after medication (P <.001), improving from a mean value of 6.44 ± 1.55 to a mean of 7.31 ± 1.24. Significant improvement was also noted in the scores for conchal color and degree of edema after the treatment had been administered (P <.001). Conclusion: The study demonstrates that Rhinapi nasal spray decreases total symptom scores, and results in improved QoL and otolaryngological examination scores. Propolis spray may be recommended for patients with allergic rhinitis alongside other treatments. [ABSTRACT FROM AUTHOR]